SinoMab BioScience Ltd represents a strong commitment to delivering innovative biopharmaceutical solutions. The company values scientific excellence, dedication to patients, and respect for employees. With a mission to improve global health, SinoMab is driven by a corporate philosophy of integrity and collaboration. By leveraging cutting-edge research and development capabilities, SinoMab strives to discover breakthrough therapies for unmet medical needs. With a focus on quality and safety, SinoMab BioScience Ltd aims to create value for patients, shareholders, and the healthcare community.

SinoMab BioScience Ltd is primarily present in Hong Kong and Mainland China.

SinoMab BioScience Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed and commercialized multiple monoclonal antibody drugs, leading to notable advancements in the field of targeted therapeutics. Additionally, SinoMab BioScience Ltd has forged strategic partnerships with renowned pharmaceutical companies, expanding its global presence and fostering collaboration for further growth. The company's dedication to research and innovation has resulted in the successful development of novel antibody therapeutics, addressing critical unmet medical needs. SinoMab BioScience Ltd's relentless pursuit of excellence has earned it a reputation as a leader in the biopharmaceutical industry, with its groundbreaking discoveries and commitment to improving patient outcomes.

SinoMab BioScience Ltd is a leading biotechnology company specializing in antibody research and development. Established in 2001, the company has rapidly grown to become a renowned player in the pharmaceutical industry. With its headquarters in Hong Kong, SinoMab has successfully expanded its operations worldwide, focusing on the discovery and production of innovative monoclonal antibodies for therapeutic treatments. By leveraging cutting-edge technologies and strategic partnerships, SinoMab has built a robust pipeline of potential drugs, targeting various diseases including cancer, inflammation, and autoimmune disorders. With a strong commitment to delivering high-quality and effective treatment options, SinoMab BioScience Ltd continues to make significant contributions to the field of biomedicine.

The main competitors of SinoMab BioScience Ltd in the market include companies such as Johnson & Johnson, Roche Holding AG, Pfizer Inc., and Novartis AG.

SinoMab BioScience Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of SinoMab BioScience Ltd is focused on the development and commercialization of innovative monoclonal antibody therapeutics. The company specializes in the research and development of novel biotherapeutics for the treatment of various diseases, including cancers and autoimmune disorders. SinoMab BioScience Ltd operates through a combination of in-house research and collaboration with academic institutions and global pharmaceutical companies. With a strong emphasis on quality and scientific excellence, the company aims to bring effective and safe therapeutic solutions to patients worldwide.

لا يمكن حساب مضاعف الربحية للسهم لـSinoMab BioScience في الوقت الحالي.

لا يمكن حالياً حساب معامل القيمة السوقية إلى العائدات لـ SinoMab BioScience.

نقاط جودة AlleAktien لـ SinoMab BioScience هي 2/10.

لا يمكن حالياً حساب الإيرادات لـSinoMab BioScience.

لا يمكن حساب الربح لـ SinoMab BioScience في الوقت الحالي.

SinoMab BioScience Ltd is a biopharmaceutical company based in Hong Kong. The company aims to develop innovative therapies and therapeutics to meet the needs of patients worldwide. SinoMab BioScience operates an integrated business model consisting of three sectors: research and development, manufacturing, and distribution of biopharmaceutical products. The company conducts intensive research and development to bring novel therapies and drugs to the market. They strive to find groundbreaking technologies and therapeutic solutions to fulfill unmet patient needs. SinoMab BioScience produces its biopharmaceutical products in accordance with international Good Manufacturing Practice (GMP) standards to ensure high product quality. The company distributes its products in China and international markets, with strategic partnership support for marketing. Currently, SinoMab BioScience offers four main products, including IBI303, IBI301, SMC-110101, and Leukotuximab, which are used for the treatment of various conditions such as lung cancer, solid tumors, macular degeneration, and acute lymphoblastic leukemia. In summary, SinoMab BioScience operates an integrated business model and offers innovative biopharmaceutical products, aiming to fulfill unmet patient needs through intensive research and development. Through strategic partnerships and international presence, the company is able to distribute its products worldwide, making a positive impact on global patient health.

يوزع SinoMab BioScience أرباحًا قدرها 0 CNY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ SinoMab BioScience في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـSinoMab BioScience هو HK0000544194.

الرمز المُختصر لـ SinoMab BioScience هو 3681.HK.

خلال آخر 12 شهراً، دفعت SinoMab BioScience توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع SinoMab BioScience خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 CNY.

نسبة توزيعات الأرباح الحالية لـ SinoMab BioScience هي .

SinoMab BioScience يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

SinoMab BioScience دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 CNY. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

SinoMab BioScience يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 CNY من SinoMab BioScience المُعلن عنها في ٨‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٨‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٨‏/٩‏/٢٠٢٤.

في العام 2023، وزعت SinoMab BioScience 0 CNY كأرباح أسهم.

يتم توزيع أرباح SinoMab BioScience بالعملة CNY.